INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in Patients With Stable Cardiovascular Disease (INTENSITY-HIGH)
Latest Information Update: 04 Dec 2023
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Ezetimibe; Rosuvastatin; Simvastatin
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms INTENSITY-HIGH
- 22 Jul 2021 Planned End Date changed from 30 Nov 2020 to 30 Nov 2023.
- 17 May 2021 Results assessing non-LDL effects of PCSK9i in stable CV disease patients who were otherwise ineligible for PCSK9i treatment, presented at the 70th Annual Scientific Session of the American College of Cardiology.
- 07 Jan 2020 Planned End Date changed from 8 May 2019 to 30 Nov 2020.